Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Conference Correspondent
ASCO 2020 Cholangiocarcinoma
ASCO 2020 Cholangiocarcinoma
Top 10 Abstracts from ASCO 2020 with Milind Javle
By
Milind M. Javle, MD
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Videos
Treatment options for cholangiocarcinoma continue to evolve. Milind Javle, MD, from MD Anderson Cancer Center, discusses some interesting abstracts from the ASCO 2020 meeting.
Read Article
Phase 2 Study of Nivolumab with Gemcitabine/Cisplatin or Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable BTC (BilT-01)
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
The combinations of nivolumab with gemcitabine/cisplatin or nivolumab with ipilimumab were tested in patients with untreated advanced biliary tract cancer.
Read Article
Combination Immunotherapy with Ipilimumab and Nivolumab in Patients with Advanced Biliary Tract Cancer
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
The response rate to the combination of ipilimumab and nivolumab in patients with advanced biliary tract cancer compared favorably to clinical trials investigating single-agent anti–PD-1 therapy.
Read Article
Phase 2 Study Assessing Tolerability, Efficacy, and Biomarkers for Durvalumab ± Tremelimumab and Gemcitabine/Cisplatin in Chemo-Naïve Advanced BTC
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
Durvalumab ± tremelimumab plus chemotherapy was well-tolerated and showed promising efficacy in chemotherapy-naïve patients with advanced biliary tract cancer.
Read Article
IDH1 Mutation Detection in ctDNA and Association with Clinical Response in Patients with Advanced iCCA from Phase 3 ClarIDHy
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
Detection of
IDH1
mutations in plasma from patients with intrahepatic cholangiocarcinoma is highly concordant with detection in tumor tissue.
Read Article
Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
The use of adjuvant chemoradiotherapy was associated with improved overall survival compared with chemotherapy alone in patients with resected extrahepatic cholangiocarcinoma.
Read Article
Retrospective Analysis of Post Second-Line Chemotherapy Outcomes with Advanced or Metastatic CCA and FGFR2 Fusions
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
In a phase 2 trial of patients with cholangiocarcinoma and
FGFR2
fusions, infigratinib administered as third- and later-line chemotherapy treatment resulted in a meaningful progression-free survival and objective response rate benefit.
Read Article
FOENIX-CCA2: Phase 2, Open-Label, Multicenter Study of Futibatinib in Patients with iCCA Harboring FGFR2 Gene Fusions
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
Preliminary data are reported for a phase 2, open-label multicenter study of futibatinib in patients with intrahepatic cholangiocarcinoma harboring
FGFR2
gene fusions or other rearrangements.
Read Article
Natural History of Fibroblast Growth Factor Receptor–Altered Cholangiocarcinoma
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
The clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations are reported based on a retrospective chart review.
Read Article
Phase 2 Study of mFOLFOX versus mFOLFIRI in Locally Advanced or Metastatic BTC Refractory to First-Line Chemotherapy
ASCO 2020 Cholangiocarcinoma
,
Cholangiocarcinoma
Conference Correspondent
This randomized phase 2 study showed that mFOLFIRI was not superior to mFOLFOX as second-line treatment of biliary tract cancer.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma